International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 2 , Pages 492-498 , 1 February 2009

Quality of Radiotherapy Reporting in Randomized Controlled Trials of Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Systematic Review

  • Justin E. Bekelman, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationReprint requests to: Justin E. Bekelman, M.D., Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Tel: (212) 639-6802; Fax: (917) 432-2312
    • ,
  • Joachim Yahalom, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Received 3 March 2008 ,Revised 14 April 2008 ,Accepted 14 April 2008.

References 

  1. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31–49
  2. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA. 1996;276:637–639
  3. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194
  4. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med. 2001;134:663–694
  5. Ottevanger PB, Therasse P, van de Velde C, et al. Quality assurance in clinical trials. Crit Rev Oncol Hematol. 2003;47:213–235
  6. Bentzen SM. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol. 1998;46:5–18
  7. The NCCN Non-Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology, version 1.2007. ©2007 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org. Accessed October 10, 2007.
  8. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?. J Clin Oncol. 2004;22:62–68
  9. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771
  10. Carde P. The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: Overweight which side?. J Clin Oncol. 2005;23:9058–9062
  11. Radiation Therapy Oncology Group . RTOG procedure manual. Philadelphia: RTOG; 2005;Available from: http://www.rtog.org/pdf_document/manual.pdf. Accessed October 20, 2007
  12. Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst. 2006;98:620–625
  13. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  14. Yahalom J. Principles, indications, and techniques of radiation therapy of lymphomas. In:  Canellos G,  Lister TA,  Young B editor. The Lymphomas. 2nd edition. Philadelphia: WB Saunders; 2006;
  15. Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol. 2002;13(Suppl. 1):79–83
  16. Muller RP, Eich HT. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG): Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol. 2005;181:557–566
  17. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol. 2006;79:270–277
  18. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study. Ann Intern Med. 1994;120:903–912
  19. Duhmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:305–310
  20. Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days—A critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys. 1991;20:13–20
  21. Fietkau R, Rodel C, Hohenberger W, et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys. 2007;67:1008–1019
  22. Gebski V, Lagleva M, Keech A, et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst. 2006;98:26–38
  23. Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: A phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol. 2005;35:195–201
  24. Bosch W, Matthews J, Straube W, et al. QuASAR: Quality assurance submission, analysis, and review system for advanced technology clinical trials in radiation therapy. In:  Bissonnette J-P editors. Proceedings of the XVth International Conference on the Use of Computers in Radiation Therapy, June 4–7, 2007. Toronto, Canada. Oakville, ON, Canada: Novel Digital Publishing; 2007;p. 98–102
  25. Eich HT, Muller RP. The radiotherapy reference panel experiences and results of the German Hodgkin Study Group (GHSG). Eur J Haematol. 2005;75(Suppl.):98–105
  26. Ikeda H. Quality assurance activities in radiotherapy. Jpn J Clin Oncol. 2002;32:493–496
  27. Poortmans PM, Davis JB, Ataman F, et al. The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: Past, present and future. Eur J Surg Oncol. 2005;31:667–674
  28. Ferreira IH, Dutreix A, Bridier A, et al. The ESTRO-QUALity assurance network (EQUAL). Radiother Oncol. 2000;55:273–284
  29. Ibbott G. The Radiological Physics Center's QA Activities. 2007. Available from: http://rpc.mdanderson.org/RPC/Publications/RPC_Presentations/RPC%20Refresher%20Course%202007.pdf. Accessed October 20, 2007.
  30. Eich HT, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma—Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys. 2007;69:1187–1192
  31. Diez P, Hoskin PJ, Aird EG. Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: Results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244). Br J Radiol. 2007;80:816–821
  32. Hill CL, LaValley MP, Felson DT. Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol. 2002;55:783–786
  33. Soares HP, Daniels S, Kumar A, et al. Bad reporting does not mean bad methods for randomised trials: Observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ. 2004;328:22–24

 Supported by the Mortimer J. Lacher, M.D. Lymphoma Fellowship (J. E. Bekelman).

 Presented in part at the American Society for Therapeutic Radiology and Oncology 48th Annual Meeting, Philadelphia, PA, November 5–9, 2006.

PII: S0360-3016(08)00818-3

doi: 10.1016/j.ijrobp.2008.04.058

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 2 , Pages 492-498 , 1 February 2009

Article Tools

* Image Usage & Resolution